-

SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 on March 7, 2023

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the fourth quarter and full year of fiscal 2022 before U.S. markets open on Tuesday, March 7, 2023. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. EST / 2:00 p.m. CET.

The call will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.

Contacts

Investor:
Katherine Bailon
VP, Investor Relations
ir@sophiagenetics.com

Media:
Nick Puleo
npuleo@comsint.com

SOPHiA GENETICS

NASDAQ:SOPH

Release Versions
$Cashtags

Contacts

Investor:
Katherine Bailon
VP, Investor Relations
ir@sophiagenetics.com

Media:
Nick Puleo
npuleo@comsint.com

Social Media Profiles
More News From SOPHiA GENETICS

SOPHiA GENETICS’ SOPHiA DDM™ HRD Solution is Tapped by Unipath Specialty Laboratory Limited

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Unipath Specialty Laboratory Limited, one of the leading diagnostic brands in India, is live on the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. Using SOPHiA GENETICS’ technology, Unipath Specialty Laboratory Limited has launched HRD Gene Panel, its latest offering in the field of ca...

SOPHiA GENETICS Celebrates Swiss Biotech Award

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, was honored to accept the Swiss Biotech Success Stories Award from the Swiss Biotech Association. The Award recognizes SOPHiA GENETICS’ contributions in leading the way to democratizing data-driven medicine. Founded in Lausanne, Switzerland, SOPHiA GENETICS has been working to democratize data-driven medicine for over a de...

The University of Maryland Medical Center Chooses SOPHiA GENETICS Technology

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the University of Maryland Medical Center (UMMC) is using SOPHiA GENETICS technology to enhance their capabilities around rare disease detection and treatment. UMMC has chosen SOPHiA Whole Exome Solution™ v2, a next-generation sequencing (NGS)-based application that provides a streamlined end-to-end wo...
Back to Newsroom